BMJ1d
AB1241 DESIGN OF AVACOSTAR: A REAL-WORLD STUDY OF AVACOPAN IN ANCA-ASSOCIATED VASCULITIS (AAV)
Background: Avacopan, a first-in-class oral C5aR antagonist, was shown to be superior to a prednisone taper in sustaining remission, and was associated with improved estimated glomerular filtration ...
BMJ2d
THU0178 Long term safety profile of methotrexate in patients with ra in routine care
Background Methotrexate is the anchor drug used most widely as monotherapy or combination therapy with other DMARDS & biologics in treatment of RA. It is widely perceived by clinicians to have ...
BMJ6d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ1d
Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation
Correspondence to Dr Naotomo Kambe, Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8507, Japan; nkambe{at}kuhp.kyoto-u.ac.jp Results The study population ...
BMJ7d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ7d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ11d
Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade
Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...
BMJ7d
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
Objectives Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE). Severe (proliferative) forms of LN are treated with induction immunosuppressive therapy (IST), ...
BMJ13d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ9d
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis
Objectives Although T cells have been implicated in the pathogenesis of systemic sclerosis (SSc), a comprehensive study of T-cell-mediated immune responses in the affected skin of patients with ...
BMJ10d
AB1027 The predictive value of cystatine c for gouty nephropathy
Background Gout is the most common cause of an inflammatory arthritis in men elder than 30 years, varies up to 1,7% of the total morbidity. One of the most common complication of chronic gout is gouty ...